Everyday Health on MSN
Experimental Obesity Drug Could Soon Compete With Wegovy and Zepbound
Drugmaker Eli Lilly said it would soon start late-stage trials for eloralintide, a drug mimicking the pancreatic hormone ...
Below, doctors explain everything you need to know about the phenomenon. It’s important to be clear upfront that “Ozempic ...
Medicare will cover GLP-1 weight loss drugs for specific patient groups, beginning in mid-2026, under a deal struck with drugmakers.
Woman's World on MSN
Dr Blitz: TrumpRx Deal for Wegovy and Zepbound ‘Just What the Doctor Ordered'
After writing dozens of GLP-1 articles over the past year, one issue that consistently comes up is the affordability of ...
A man who fainted in the Oval Office last week was a patient of a weight-loss drug company, according to reports.
There’s plenty to like about the lower direct-to-consumer prices the White House negotiated with Eli Lilly and Novo Nordisk. There are also caveats and some unanswered questions.
The deal involves Eli Lilly, which makes Zepbound and Mounjaro, and Novo Nordisk, the maker of Ozempic and Wegovy. The drugs, known as GLP-1 medications, now cost as much as $1350 a month. Under the ...
Oral GLP-1 weight loss pills could replace injections by March 2026 at $150 monthly, Medicare chief Dr. Mehmet Oz predicted in a FOX Business appearance.
The White Houes may have struck a deal with Eli Lilly and Novo Nordisk last week to lower the costs of their weight loss ...
Pfizer Chief Executive Albert Bourla had long searched for an obesity drug to make up for dwindling sales of the pharma ...
Despite President Trump’s claims, scientists don’t have enough evidence to say acetaminophen use during pregnancy is linked ...
Pfizer won its fight to buy obesity-drug maker Metsera, with an extra $1.7 billion and a little help from the Trump administration. Pfizer Inc. pulled off a comeback win, beating out Danish drug giant ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results